We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Avacta Group Plc | LSE:AVCT | London | Ordinary Share | GB00BYYW9G87 | ORD 10P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.25 | -0.53% | 46.50 | 46.00 | 47.00 | 46.50 | 45.25 | 45.75 | 2,892,374 | 15:06:30 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 10.06M | -39.19M | -0.1382 | -3.36 | 131.88M |
TIDMAVCT
RNS Number : 5835I
Avacta Group PLC
31 August 2016
31 August 2016
Avacta Group plc
("Avacta" or "the Group" or "the Company")
Change of Registered Office
Avacta Group plc (AIM: AVCT), the developer of Affimer(R) biotherapeutics and research reagents, is pleased to announce that it has changed the address of its registered office to Unit 20, Ash Way, Thorp Arch Estate, Wetherby, LS23 7FA.
ENDS
Notes to Editors
For further information from Avacta Group plc, please contact:
Avacta Group plc Tel: +44 (0) Alastair Smith, Chief Executive 844 414 0452 Officer www.avacta.com Tony Gardiner, Chief Financial Officer Numis Securities Limited Tel: +44 (0) Michael Meade / Freddie Barnfield 207 260 1000 - Nominated Adviser www.numiscorp.com James Black - Corporate Broking WG Partners Tel: +44 (0) David Wilson 203 705 9318 Nigel Barnes Tel: +44 (0) Claes Spang 203 705 9217 www.wgpartners.co.uk FTI Consulting (Financial Media Tel: +44 (0) and IR) 203 727 1000 Simon Conway / Natalie Garland-Collins avacta@fticonsulting.com
About Avacta Group plc (www.avacta.com)
Avacta's principal focus is on its proprietary Affimer(R) technology which is a novel engineered alternative to antibodies that has wide application in Life Sciences for diagnostics, therapeutics and general research and development.
Antibodies dominate markets worth in excess of $75bn despite their shortcomings. Affimer technology has been designed to address many of these negative performance issues, principally; the time taken to generate new antibodies, the reliance on an animal's immune response, poor specificity in many cases, and batch to batch variability. Affimer technology is based on a small protein that can be quickly generated to bind with high specificity and affinity to a wide range of targets to enable diagnostics, research assays and therapeutics.
Avacta has a pre-clinical therapeutic development programme with an in-house focus on immuno-oncology and bleeding disorders as well as partnered development programmes. Avacta is commercialising non-therapeutic Affimer reagents through licensing to developers of life sciences research tools and diagnostics.
This information is provided by RNS
The company news service from the London Stock Exchange
END
CROSDMFDFFMSEFA
(END) Dow Jones Newswires
August 31, 2016 09:17 ET (13:17 GMT)
1 Year Avacta Chart |
1 Month Avacta Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions